RedHill Biopharma (RDHL) Operating Leases (2019 - 2025)

RedHill Biopharma (RDHL) has reported Operating Leases for 7 consecutive years, with $170000.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Operating Leases fell 51.84% year-over-year to $170000.0 in Q4 2025; TTM through Dec 2025 was $170000.0, a 51.84% decrease from a year earlier, with the FY2025 full-year figure at $170000.0, down 51.84% from the prior year.
• Operating Leases was $170000.0 for Q4 2025 at RedHill Biopharma, down from $214000.0 in the prior quarter.
• Over five years, Operating Leases peaked at $1.7 million in Q3 2021 and troughed at $170000.0 in Q4 2025.
• A 5-year average of $1.0 million and a median of $1.0 million in 2022 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases surged 33.22% in 2021 and slumped 71.47% in 2024, its largest moves.
• Over 5 years, Operating Leases stood at $1.6 million in 2021, then sank by 36.22% to $1.0 million in 2022, then slumped by 30.43% to $718000.0 in 2023, then plunged by 50.84% to $353000.0 in 2024, then tumbled by 51.84% to $170000.0 in 2025.
• The last three Operating Leases figures came in at $170000.0 (Q4 2025), $214000.0 (Q2 2025), and $353000.0 (Q4 2024), per Business Quant data.